Fulvestrant Mylan 250 mg solution for injection in prefilled syringe clinical trials

C4251003- A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations.

This study is looking at a new combination of medicines for people with certain advanced cancers where previous treatments haven't worked well. It aims to see how many people respond to the treatment.